STAT3 in the systemic inflammation of cancer cachexia

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Weight loss is diagnostic of cachexia, a debilitating syndrome contributing mightily to morbidity and mortality in cancer. Most research has probed mechanisms leading to muscle atrophy and adipose wasting in cachexia; however cachexia is a truly systemic phenomenon. Presence of the tumor elicits an inflammatory response and profound metabolic derangements involving not only muscle and fat, but also the hypothalamus, liver, heart, blood, spleen and likely other organs. This global response is orchestrated in part through circulating cytokines that rise in conditions of cachexia. Exogenous Interleukin-6 (IL6) and related cytokines can induce most cachexia symptomatology, including muscle and fat wasting, the acute phase response and anemia, while IL-6 inhibition reduces muscle loss in cancer. Although mechanistic studies are ongoing, certain of these cachexia phenotypes have been causally linked to the cytokine-activated transcription factor, STAT3, including skeletal muscle wasting, cardiac dysfunction and hypothalamic inflammation. Correlative studies implicate STAT3 in fat wasting and the acute phase response in cancer cachexia. Parallel data in non-cancer models and disease states suggest both pathological and protective functions for STAT3 in other organs during cachexia. STAT3 also contributes to cancer cachexia through enhancing tumorigenesis, metastasis and immune suppression, particularly in tumors associated with high prevalence of cachexia. This review examines the evidence linking STAT3 to multi-organ manifestations of cachexia and the potential and perils for targeting STAT3 to reduce cachexia and prolong survival in cancer patients.

Original languageEnglish (US)
JournalSeminars in Cell and Developmental Biology
DOIs
StateAccepted/In press - Jan 7 2016

Fingerprint

Cachexia
Inflammation
Neoplasms
Acute-Phase Reaction
Fats
Cytokines
Muscles
Interleukin-6
STAT3 Transcription Factor
Muscular Atrophy
Hypothalamus
Anemia
Weight Loss
Carcinogenesis
Skeletal Muscle
Spleen

Keywords

  • Adipose tissue
  • Atrophy
  • Cachexia
  • Cancer
  • Dysmetabolism
  • Fat
  • Gonad
  • Inflammation
  • Liver
  • Skeletal muscle
  • Transcription regulation
  • Wasting

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

STAT3 in the systemic inflammation of cancer cachexia. / Zimmers, Teresa; Fishel, Melissa; Bonetto, Andrea.

In: Seminars in Cell and Developmental Biology, 07.01.2016.

Research output: Contribution to journalArticle

@article{bdaed6695e5a4755be3e67c20074c17e,
title = "STAT3 in the systemic inflammation of cancer cachexia",
abstract = "Weight loss is diagnostic of cachexia, a debilitating syndrome contributing mightily to morbidity and mortality in cancer. Most research has probed mechanisms leading to muscle atrophy and adipose wasting in cachexia; however cachexia is a truly systemic phenomenon. Presence of the tumor elicits an inflammatory response and profound metabolic derangements involving not only muscle and fat, but also the hypothalamus, liver, heart, blood, spleen and likely other organs. This global response is orchestrated in part through circulating cytokines that rise in conditions of cachexia. Exogenous Interleukin-6 (IL6) and related cytokines can induce most cachexia symptomatology, including muscle and fat wasting, the acute phase response and anemia, while IL-6 inhibition reduces muscle loss in cancer. Although mechanistic studies are ongoing, certain of these cachexia phenotypes have been causally linked to the cytokine-activated transcription factor, STAT3, including skeletal muscle wasting, cardiac dysfunction and hypothalamic inflammation. Correlative studies implicate STAT3 in fat wasting and the acute phase response in cancer cachexia. Parallel data in non-cancer models and disease states suggest both pathological and protective functions for STAT3 in other organs during cachexia. STAT3 also contributes to cancer cachexia through enhancing tumorigenesis, metastasis and immune suppression, particularly in tumors associated with high prevalence of cachexia. This review examines the evidence linking STAT3 to multi-organ manifestations of cachexia and the potential and perils for targeting STAT3 to reduce cachexia and prolong survival in cancer patients.",
keywords = "Adipose tissue, Atrophy, Cachexia, Cancer, Dysmetabolism, Fat, Gonad, Inflammation, Liver, Skeletal muscle, Transcription regulation, Wasting",
author = "Teresa Zimmers and Melissa Fishel and Andrea Bonetto",
year = "2016",
month = "1",
day = "7",
doi = "10.1016/j.semcdb.2016.02.009",
language = "English (US)",
journal = "Seminars in Cell and Developmental Biology",
issn = "1084-9521",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - STAT3 in the systemic inflammation of cancer cachexia

AU - Zimmers, Teresa

AU - Fishel, Melissa

AU - Bonetto, Andrea

PY - 2016/1/7

Y1 - 2016/1/7

N2 - Weight loss is diagnostic of cachexia, a debilitating syndrome contributing mightily to morbidity and mortality in cancer. Most research has probed mechanisms leading to muscle atrophy and adipose wasting in cachexia; however cachexia is a truly systemic phenomenon. Presence of the tumor elicits an inflammatory response and profound metabolic derangements involving not only muscle and fat, but also the hypothalamus, liver, heart, blood, spleen and likely other organs. This global response is orchestrated in part through circulating cytokines that rise in conditions of cachexia. Exogenous Interleukin-6 (IL6) and related cytokines can induce most cachexia symptomatology, including muscle and fat wasting, the acute phase response and anemia, while IL-6 inhibition reduces muscle loss in cancer. Although mechanistic studies are ongoing, certain of these cachexia phenotypes have been causally linked to the cytokine-activated transcription factor, STAT3, including skeletal muscle wasting, cardiac dysfunction and hypothalamic inflammation. Correlative studies implicate STAT3 in fat wasting and the acute phase response in cancer cachexia. Parallel data in non-cancer models and disease states suggest both pathological and protective functions for STAT3 in other organs during cachexia. STAT3 also contributes to cancer cachexia through enhancing tumorigenesis, metastasis and immune suppression, particularly in tumors associated with high prevalence of cachexia. This review examines the evidence linking STAT3 to multi-organ manifestations of cachexia and the potential and perils for targeting STAT3 to reduce cachexia and prolong survival in cancer patients.

AB - Weight loss is diagnostic of cachexia, a debilitating syndrome contributing mightily to morbidity and mortality in cancer. Most research has probed mechanisms leading to muscle atrophy and adipose wasting in cachexia; however cachexia is a truly systemic phenomenon. Presence of the tumor elicits an inflammatory response and profound metabolic derangements involving not only muscle and fat, but also the hypothalamus, liver, heart, blood, spleen and likely other organs. This global response is orchestrated in part through circulating cytokines that rise in conditions of cachexia. Exogenous Interleukin-6 (IL6) and related cytokines can induce most cachexia symptomatology, including muscle and fat wasting, the acute phase response and anemia, while IL-6 inhibition reduces muscle loss in cancer. Although mechanistic studies are ongoing, certain of these cachexia phenotypes have been causally linked to the cytokine-activated transcription factor, STAT3, including skeletal muscle wasting, cardiac dysfunction and hypothalamic inflammation. Correlative studies implicate STAT3 in fat wasting and the acute phase response in cancer cachexia. Parallel data in non-cancer models and disease states suggest both pathological and protective functions for STAT3 in other organs during cachexia. STAT3 also contributes to cancer cachexia through enhancing tumorigenesis, metastasis and immune suppression, particularly in tumors associated with high prevalence of cachexia. This review examines the evidence linking STAT3 to multi-organ manifestations of cachexia and the potential and perils for targeting STAT3 to reduce cachexia and prolong survival in cancer patients.

KW - Adipose tissue

KW - Atrophy

KW - Cachexia

KW - Cancer

KW - Dysmetabolism

KW - Fat

KW - Gonad

KW - Inflammation

KW - Liver

KW - Skeletal muscle

KW - Transcription regulation

KW - Wasting

UR - http://www.scopus.com/inward/record.url?scp=84961147160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961147160&partnerID=8YFLogxK

U2 - 10.1016/j.semcdb.2016.02.009

DO - 10.1016/j.semcdb.2016.02.009

M3 - Article

JO - Seminars in Cell and Developmental Biology

JF - Seminars in Cell and Developmental Biology

SN - 1084-9521

ER -